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Background: AMG 416 is a novel peptide agonist of the calcium-sensing receptor (CaSR). This report describes the
activity of AMG 416 in two different rodent models of uremia, compared in each case to cinacalcet, an approved
therapeutic for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease on dialysis.
Methods: AMG 416 was administered as a single intravenous (IV) bolus in a severe, acute model of renal
insufficiency (the “1K1C” model) and plasma parathyroid hormone (PTH) and serum calcium levels were monitored
for 24 hours. In a chronic, less severe model of renal dysfunction, the 5/6 nephrectomy (5/6 Nx) model, AMG 416
was administered as a once-daily IV bolus for 28 days. Both studies included a control (vehicle) group and a comparison
cinacalcet group (po dosing at 30 mg/kg and 10 mg/kg for the 1K1C and 5/6 Nx studies, respectively).
Results: Administration of AMG 416 by IV bolus injection into rats with acute renal dysfunction (1K1C model)
resulted in a sustained reduction in plasma PTH from the initial elevated values. Following a single IV bolus
(0.5 mg/kg), AMG 416 caused a substantial drop in PTH levels which remained approximately 50% below their
initial level at 24 hrs. In the same model, oral treatment with cinacalcet (30 mg/kg) resulted in an acute drop in
PTH which almost returned to the starting level by 24 hours after dosing. In the 5/6 Nx chronic uremia model,
daily IV dosing of AMG 416 over 4 weeks (1 mg/kg) resulted in a sustained reduction in PTH, with approximately
50% of the initial level observed 48 hours post treatment throughout the study. Cinacalcet treatment (10 mg/kg)
in the same model resulted in acutely lowered plasma PTH levels which returned to placebo levels by 24 hours
post-dose. Consistent with the reductions in plasma PTH, reductions in serum calcium were observed in both
AMG 416- and cinacalcet-treated animals.
Conclusions: As a long-acting CaSR agonist suitable for administration by the IV route, AMG 416 is a potential
new therapy for the treatment of CKD patients with SHPT receiving hemodialysis.
Keywords: Calcium-sensing receptor, Secondary hyperparathyroidism (SHPT), Chronic kidney disease (CKD),
Uremic rat model, AMG 416Background
Chronic kidney disease (CKD) is a condition characterized
by a gradual loss of kidney function. As a consequence
of reduced renal function, normal mineral regulatory
mechanisms are disrupted. CKD is often further com-
plicated by the development of secondary hyperpara-
thyroidism (SHPT) due to these disturbances in mineral
metabolism [1]. Increased PTH secretion in response to
hypocalcemia is mediated by the calcium-sensing receptor* Correspondence: dmaclean@amgen.com
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unless otherwise stated.(CaSR) a G-protein coupled receptor (GPCR) located on
the parathyroid glands [2].
The use of the calcimimetic agent cinacalcet (Sensipar®/
Mimpara®) [3] has represented an advance in the manage-
ment of patients with SHPT receiving dialysis. Cinacalcet
is an allosteric modulator of the CaSR that sensitizes
the receptor to extracellular calcium, resulting in re-
duced PTH secretion from the parathyroid gland [4].
The decrease in PTH is accompanied by reductions in
serum calcium and phosphorus levels in patients with
SHPT receiving dialysis [3].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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is being developed as an intravenous (IV) product for
the treatment of CKD with SHPT. In a recent publica-
tion, we showed that AMG 416 is effective at reducing
plasma PTH in preclinical uremic rat studies, modifying
parathyroid gland receptor levels and impacting calcium
and phosphorus levels [5]. AMG 416 has also proven ef-
fective in clinical studies in both normal healthy males
and CKD patients with SHPT receiving hemodialysis
[6,7]. With the IV route of administration, AMG 416 is
anticipated to have improved compliance relative to
cinacalcet, and offers the potential for improved toler-
ability. In this paper, we sought to directly compare the
efficacy of these two compounds in two different uremic
rodent models. We chose a quite severe, acute model of
renal insufficiency (the 1 kidney removal and 1 clip, or
“1K1C” model) to examine the efficacy of a single IV
dose of AMG 416 vs oral cinacalcet in the presence of
elevated PTH and serum creatinine. In addition, we ex-
amined the activity of AMG 416 in a model of chronic
uremia, in rats under 5/6 nephrectomy in order to com-
pare the efficacy of AMG 416 and cinacalcet over repeated
dosing during a 28-day administration period.
Methods
Test compounds
AMG 416 was prepared as described previously [5].
Cinacalcet was prepared from commercial tablets as a
suspension in normal saline.
Evaluation of AMG 416 in “1 Kidney 1 Clip” (1K1C) rat
model of acute renal dysfunction
The 1K1C model was based on the original model devel-
oped by Goldblatt [8]. Male Sprague Dawley (SD) rats
(~300 g) were purchased from Charles River Laborator-
ies (CRL), pre-cannulated in the jugular and femoral
veins for blood sampling and dosing, respectively. The
study protocol was approved by the Institutional Animal
Care and Use Committee (IACUC) of KAI Pharmaceuti-
cals, Inc. General anesthesia was induced and maintained
by intraperitoneal (IP) injection of sodium pentobarbital
(5.2%, 0.4 mL/rat). Both kidneys were exposed via laparot-
omy. The right kidney was removed following ligation of
the right renal pedicle and ureter. A microvascular clip
was applied to the left renal artery for 45 min and then re-
moved. Ischemia was assessed by color change in the af-
fected kidney. The abdominal incision was then closed
and the animal was allowed to recover for approximately
48 hrs prior to dosing. Animals were treated with either
AMG 416 (0.5 mg/kg in 0.5 mL, IV; n = 5), saline (0.5 mL,
IV; n = 3) or cinacalcet (30 mg/kg, 1 mL po; n = 6). Ani-
mals were given free access to food and water. Blood
samples (~0.2 mL) were taken from the jugular cannula
under anesthesia (2% isoflurane in O2). Samples weretaken at the indicated times and processed immediately
for plasma.
Evaluation of AMG 416 in 5/6 Nephrectomized Rats
A 4-week, repeat dose study was performed in 5/6
nephrectomized male SD rats at CRL (Wilmington, MA).
The protocol was approved by the IACUC of CRL. Ani-
mals weighed ~300 g at the time of the first surgery. In
the first operation, 2/3 of one kidney was surgically re-
moved. After a one-week recovery, the other kidney was
removed, leaving the rat with 1/6 of its original renal
capacity. Catheters were implanted in each jugular vein
during the second operation for drug administration
and blood sampling. Animals were allowed to recover
for 9-10 days following surgery prior to dosing. Thirty-
six animals were included in the study. Animals were
randomized to study drug based on serum creatinine
and plasma PTH collected on Days -3 and -2 (~7 days
post final surgery; data averaged to determine “pre-dose”
value). Twelve animals per group received daily adminis-
tration of saline (0.5 mL, IV bolus) or AMG 416 (1 mg/kg
in 0.5 mL, IV bolus) or cinacalcet (10 mg/kg in 1 mL, oral
gavage) for 28 days. Blood samples (0.45 mL; tail vein)
were taken for PTH and calcium analysis prior to dosing
and at 6 and 16 hrs post-dose on Days 7, 14, 21 and 28.
Animals were sacrificed on Day 30 (48 hrs after the last
dose) and blood was taken for PTH analysis. Due to
mortality during the study, group sizes for PTH and Ca
analysis were 7, 6 and 9 for saline, cinacalcet and AMG
416, respectively.
Plasma and serum analysis
Plasma PTH levels were quantified according to the man-
ufacturer’s protocol using rat (1-84) bioactive intact PTH
ELISA kits from Immutopics International (Rat: #60-2700;
San Clemente, California). Raw data were analyzed with
GraphPad Prism (GraphPad, La Jolla, California). When
appropriate, one-way ANOVA was used to determine stat-
istical significance with Bonferroni post-test analysis.
Serum was obtained by allowing blood samples (0.2 –
0.3 mL) to clot for approximately 30-60 minutes followed
by centrifugation. Creatinine concentration was deter-
mined according to the manufacturer’s protocol using
the QuantiChrom™ kit, (DICT-500; BioAssay Systems,
Hayward, CA). Serum samples were analyzed for total
calcium content at SRI (Menlo Park, CA) using the
Roche Cobas C-501 autoanalyzer.
Results
AMG 416 suppresses PTH in animals with severely
compromised renal function
To mimic the pathology of renal failure and the associated
increases in PTH that are seen in ESRD patients with
chronic kidney disease, mineral and bone disorder (CKD-























Figure 2 AMG 416 administration lowers PTH in a severe
model of kidney dysfunction. Rats subjected to IKIC surgery were
treated with a single dose of either: AMG 416 by IV bolus injection
(0.5 mg/kg), cinacalcet by po administration (30 mg/kg), or saline IV
bolus (0.5 mL). Serum creatinine levels (mg/dL) for the three groups
were: AMG 416 (5.5), cinacalcet (5.1), saline (6.1). Blood samples were
removed at indicated times to measure plasma PTH. Mean group
baseline PTH levels (pg/mL) prior to dosing were: AMG 416 (667),
cinacalcet (949), saline (1026). Data are presented as group mean ±
SEM (AMG 416, n = 5; cinacalcet n = 6; saline, n = 3). *, p < 0.05 vs.
saline.
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http://www.biomedcentral.com/1471-2369/15/81MBD), AMG 416 (Figure 1) was evaluated in a rat model
of acute renal insufficiency (“1K1C” model). Unlike the
less severe 5/6 nephrectomy model, animals subjected to
this procedure have almost no kidney function, and highly
elevated serum creatinine and plasma PTH levels (group
mean of 5.4 mg/dL and 865 pg/mL respectively); in these
ways the model parallels ESRD. Forty-eight hours after
surgery, animals were administered a single IV bolus of
AMG 416 (0.5 mg/kg), saline or a single po dose of cina-
calcet (30 mg/kg). Administration of AMG 416 resulted in
a rapid and substantial (>90%) reduction in plasma PTH
within 1-2 hr (Figure 2). This reduction in plasma PTH
levels was maintained over the entire 24 hr monitoring
period (p < 0.05 vs saline at 24 hr). Treatment with cina-
calcet also lowered plasma PTH in this model, consistent
with previous reports [8], but to a lesser extent and for a
shorter duration than seen with AMG 416. Animals
treated with vehicle showed no reduction in PTH during
the study.
AMG 416 treatment results in prolonged PTH suppression
in a rat model of chronic kidney disease
AMG 416 was also evaluated in a rat model of chronic
kidney disease (the 5/6 nephrectomy model or 5/6 Nx),
a commonly used model of CKD-MBD that enables
chronic dosing [9]. Approximately 1 week after completion
of the 5/6 Nx surgery, animals were randomized based
upon PTH and serum creatinine values to one of three
treatment groups: saline (IV), cinacalcet (10 mg/kg po) or
AMG 416 (1 mg/kg IV). Animals were dosed daily for
28 days.
Prior to dosing, mean plasma PTH levels in all three
dose groups were similar (400 - 500 pg/mL), and elevated
in comparison to normal animals (~150 pg/mL). Serum
creatinine levels were also increased with group mean
values of 1.4, 1.3 and 1.3 mg/dL for the saline, cinacalcet
and AMG 416 groups, respectively. During the study,
PTH levels were measured pre-dose and 6 and 16 hr after
dosing on Days 7, 14, 21 and 28, and also 48 hr after the
final dose (Day 28). In the saline-treated group, plasma
PTH levels fluctuated over the 4-week study but generally
remained at or above the 400-500 pg/mL starting level
(Figure 3A). In contrast, acute reductions in plasma PTH
levels were observed in both cinacalcet- and AMG 416-
treated animals (Table 1). This is shown in Table 1 and





Figure 1 Structure of AMG 416.plasma PTH was reduced by approximately 70-90% from
baseline in both the AMG 416- and cinacalcet-treated
groups; however, by 16 hr post dosing, plasma PTH had
returned to pre-dose levels in the cinacalcet animals, com-
parable to levels seen in saline-treated animals. In con-
trast, for AMG 416-treated animals, PTH levels remained
suppressed at the 16 hr time point and were still 40-50%
reduced from baseline values at 48 hr following dosing
(on Day 28). As shown in Figure 3A, PTH was consist-
ently lower for AMG 416-treated rats at 16 hr post dosing
than for the cinacalcet or vehicle groups throughout the
4 weeks of treatment.
Consistent with the reductions in plasma PTH, modest
reductions in serum calcium were observed in both AMG
416- and cinacalcet-treated animals at 6 hr post dosing
and, consistent with the prolonged reductions in PTH,
were still reduced in the AMG 416 animals at 16 hr post
dosing (Figure 3C).
Discussion
The 1K1C model is a severe, acute model of renal dys-
function which enables the activity of AMG 416 and cina-
calcet to be investigated in the presence of the highly
elevated levels of PTH and lack of kidney function typic-
ally seen in CKD-MBD patients receiving hemodialysis
[1]. Due to its acute nature, the 1K1C model is not associ-
ated with the parathyroid gland hyperplasia seen in the rat
5/6 Nx uremic model and in dialysis patients with SHPT















































































Figure 3 Repeat administration of AMG 416 results in extended reduction of PTH in renally compromised rats. Rats subjected to 5/6
nephrectomy were treated daily for 28 days with either: AMG 416 (1 mg/kg administered by IV bolus), saline (IV bolus) or cinacalcet (10 mg/kg
administered po). Blood chemistries are reported relative to the last (day 28) dose. (A) Plasma PTH measured at 6, 16 and 48 hr from the last
dose. (B) Plasma PTH measured at 16 hr following dosing on Days 7, 14, 21 and 28. (C) Serum calcium at pre-dose, 6 and 16 h from the last dose.
Data are presented as group mean ± SEM (Saline [hatched bars] n = 7; cinacalcet [white bars] n = 6; AMG 416 [black bars] n = 9). *, p < 0.05 vs.
saline; #, p < 0.01 vs. saline; **, p < 0.001 vs. saline; ^, p < 0.01 vs. cinacalcet; ≠, p < 0.001 vs. cinacalcet, saline; +, p < 0.05 vs. cinacalcet.
Table 1 PTH (pg/mL) and Ca (mg/dL) levels in 5/6 Nx
repeat-dose study
PTH
Week Hour post dosing Cinacalcet AMG 416 Vehicle
Week 1 6 hr 128 ± 44 30 ± 6 758 ± 191
16 hr 312 ± 72 155 ± 30 472 ± 126
Week 4 6 hr 115 ± 73 18 ± 4 451 ± 162
16 hr 700 ± 315 66 ± 18 357 ± 69
Calcium
Week Hour post dosing Cinacalcet AMG 416 Vehicle
Week 1 6 hr 8.9 ± 0.3 8.0 ± 0.3 10.4 ± 0.3
16 hr 10.0 ± 0.3 8.5 ± 0.3 11.0 ± 0.3
Week 4 6 hr 9.3 ± 0.4 8.9 ± 0.3 10.7 ± 0.2
16 hr 10.3 ± 0.5 9.2 ± 0.4 11.1 ± 0.2
Data shown are group means ± SEM.
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PTH-lowering activity in the background of severe kidney
dysfunction. In this study, plasma PTH levels were signifi-
cantly reduced by a single dose of either AMG 416 or
cinacalcet. The effect of cinacalcet on PTH was of a lesser
extent and shorter duration than seen with AMG 416,
which maintained PTH lowering for more than 24 hr. The
prolonged suppression of plasma PTH in the 1K1C model
by AMG 416 is consistent with the pharmacokinetics (PK)
observed for AMG 416 in normal rats and in different
uremic models [5]. The absence of kidney function results
in an extended terminal half life for AMG 416, indicating
that the kidney is a major clearance organ for the peptide
[5]. In contrast, the half-life of cinacalcet is independent
of kidney function [11], as the main route of clearance
is through hepatic mechanisms [12]. Consistent with the
animal data and modeling PK studies, IV administration
of AMG 416 to hemodialysis patients with SHPT resulted
in dose-dependent, sustained control of PTH throughout
the interdialytic period [6].
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in preclinical models of SHPT such as effects on PTH,
serum phosphorus and calcium levels and parathyroid
gland hyperplasia. In these studies, we focused on how
AMG 416 compared with an approved calcimimetic, cina-
calcet, at lowering plasma PTH. Additional rodent studies
document the changes to parathyroid gland biology that
can take place with chronic AMG 416 treatment [5], and
the molecule’s effects on serum phosphorus levels have
been shown in the clinical setting [6,13]. For technical
reasons it was not possible to obtain data for serum
phosphorus in these studies.
The dose of cinacalcet in the chronic study was chosen
based upon PK exposure data in rats since the area under
the curve (AUC) was comparable to CKD-MBD patients
with SHPT receiving hemodialysis receiving the 60 mg
dose [9,14] and is consistent with a number of published
studies using cinacalcet [9,15]. The resulting pharmaco-
dynamic behavior for cinacalcet in this study is also
consistent with previously published results [9]. Although
treatment with both agents reduced PTH shortly after
dosing (6 hr post treatment), only AMG 416 was associ-
ated with sustained PTH reductions throughout and be-
yond the dosing interval. Throughout the four weeks of
treatment in this study, animals treated with AMG 416
maintained a consistent, lower level of plasma PTH when
compared with cinacalcet or placebo groups. These longer-
term effects may in part arise from reversal of abnormal
parathyroid gland physiology, as observed in other studies
with AMG 416 [5].
In addition to attenuating plasma PTH in both models,
both cinacalcet and AMG 416 caused a decrease in serum
calcium, in agreement with previously reported studies
with cinacalcet treatment in normal and uremic rats [4,9]
as well as in dialysis patients with SHPT [3], and consist-
ent with the known pharmacological action of lowering
PTH with this class of therapies.. This reduction in cal-
cium can persist beyond the PTH lowering effect. In re-
sponse to reduced serum calcium, a “rebound” in PTH
can occur as the body perceives a state of hypocalcemia.
This is seen in Table 1 and Figure 3B, where the
cinacalcet-treated animals show an increased PTH level
over baseline at the 16 hour time point.
Conclusions
Taken together, these findings demonstrate that AMG 416
suppresses plasma PTH and is a potential new therapy
for the treatment of CKD patients with SHPT receiving
hemodialysis. Because AMG 416 is administered by the
IV route, it is anticipated that it may have improved effi-
cacy and superior compliance compared with cinacalcet
in this indication [16]. In addition, AMG 416 offers the
potential for improved gastrointestinal tolerability over
cinacalcet [3,17], and because it is not metabolized bythe liver and does not interact with P450 enzymes [17],
avoids the risk of P450-mediated drug-drug interactions.
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